Nov 15, 2017
The JP Morgan Healthcare Conference, or “JPM”, is the healthcare conference of the year. Companies from all over the world convene in San Francisco to setup meetings with investors, prospective partners, service providers, etc. and lay the groundwork for much of the...
Aug 15, 2017
A few months ago, I posted a related article about deal timing titled ‘Maintaining Deal Momentum in the Summer Months’. Now it is early August, and we are deep in the summer slowdown. Many of us are enjoying the last stints of our summer holidays before returning to...
Mar 2, 2017
The FDA Amendments Act of 2007 created an incentive system for drug developers to pursue tropical neglected diseases, whereby upon approval of a product for a designated tropical disease, the drug developer would receive a voucher that could be applied to receive a...
Feb 22, 2017
This has certainly been an eventful few months for Immunomedics and its largest shareholder, venBio. In case you haven’t been following, below is a brief replay: Towards the end of last year, venBio, the beneficial owner of approximately 9.9% of the outstanding...
Feb 15, 2017
It has happened. After years of blood, sweat, and tears, the lead compound has made it to Phase 3 pivotal studies. Patients, physicians, the company team and investors all wait patiently for recruitment to complete and data to be collected, hoping to improve patient...
Dec 14, 2016
Last week, both chambers of Congress voted nearly unanimously to pass the 21st Century Cures Act (the Cures Act), sweeping legislation that directly impacts the government funding and FDA review process of medical innovations, both pharmaceutical and device. ...
